Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adhansia XR
- Development stage
- Discontinued
- Lead developer
- Adlon Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Adhansia XR is a once-daily, extended-release oral capsule formulation of methylphenidate hydrochloride, a central nervous system (CNS) stimulant. It is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The medication utilizes a multi-layer bead technology with both immediate- and controlled-release components to provide rapid onset (within one hour) and sustained effect for up to 16 hours post-dose. Methylphenidate acts primarily by blocking the reuptake of norepinephrine and dopamine into presynaptic neurons in the brain, thereby increasing their availability in the synaptic cleft. This mechanism enhances attention and reduces impulsivity and hyperactivity associated with ADHD. Adhansia XR carries a boxed warning for abuse potential and dependence due to its stimulant properties[1][2][3].
- Brand names
- Adhansia XR
- Other names
- methylphenidate hydrochloride extended-releasemethylphenidate HCl ERmethylphenidate HCL extended-release capsules
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on Adhansia XR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adhansia XR.